Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Neff, Guy [2 ]
Gunn, Nadege [3 ]
Flyer, Abigail [4 ]
MacConell, Leigh [5 ]
机构：
[1] Pinnacle Clin Res, San Antonio, TX USA
[2] Covenant Metab Specialists, Sarasota, FL USA
[3] Impact Res Inst, Waco, TX USA
[4] Pacific Northwest Stat Consulting, Woodinville, WA USA
[5] HighTide Therapeut, Rockville, MD USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-227
引用
收藏
页码：S614 / S615
页数：2
相关论文
共 50 条
  • [31] EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH
    Lai, M.
    Frick, A.
    Juneja, K.
    Koch, B.
    Milligan, S.
    Natha, M.
    Radtchenko, J.
    Younossi, Z.
    Afdhal, N.
    VALUE IN HEALTH, 2020, 23 : S143 - S144
  • [32] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [33] GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?
    Stoll, Lisa
    Lo, James C.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (08): : 937 - 938
  • [34] Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
    Fazeli, Sasan
    Ehrhardt, Nicole
    DIABETES, 2018, 67
  • [35] Adherence and Persistence with Type 2 Diabetes (T2DM) Medications: Saxagliptin, Sulfonylureas (SU), Thiazolidinediones (TZD), and Glucagon-Like Peptide 1 (GLP-1) Agonists
    Curkendall, Suellen M.
    Thomas, Nina
    Bell, Kelly F.
    Pan, Katy
    Juneau, Paul
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 418 - 419
  • [36] Weekly GLP-1 Agonist Albiglutide Monotherapy Improves Glycemic Parameters in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lin
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    DIABETES, 2016, 65 : A266 - A266
  • [37] Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
    Harrison, Stephen A.
    Frias, Juan P.
    Lucas, K. Jean
    Reiss, Gary
    Neff, Guy
    Bollepalli, Sureka
    Su, Yan
    Chan, Doreen
    Tillman, Erik J.
    Moulton, Ali
    de Temple, Brittany
    Zari, Arian
    Shringarpure, Reshma
    Rolph, Timothy
    Cheng, Andrew
    Yale, Kitty
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (01) : 103 - 113
  • [38] Tolerability, Safety, PK/PD of Once-Weekly Administration of GLP-1 Analogue in T2DM Patients in China and US
    Liu, Ying
    Lv, Yuan
    Guo, Xiaohui
    Zhao, Caiyun
    Zhang, Junqing
    Wei, Minji
    Tracey, Gregory J.
    Lasseter, Kenneth C.
    Xu, Michael
    DIABETES, 2017, 66 : A296 - A296
  • [39] THE IMPACT OF GLP-1 INDUCED NAUSEA AND VOMITING ON WORK PRODUCTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH T2DM
    McLeod, L.
    Sikirica, M., V
    Davenport, E.
    Sweeney, C. T.
    Joshi, A., V
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [40] Treatment with the GLP-1 analogue liraglutide is associated with inflammatory arthritis DAS28 reduction in patients with concomitant T2DM
    Sullivan, C.
    Doran, M.
    Kane, D.
    O'Shea, D.
    Mullan, R. H.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S101 - S101
12345